Search bioRxiv⌕ Search

Biology subjects

Reveret, L.

Publications and source records attributed to Reveret, L..

3 recordsLinked to original sources

Parkinson's disease risk factors are expressed at brain barriers.

Parkinsons disease (PD) is characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta, but whether its etiology is cell autonomous remains unclear. Increasing evidence implicates the blood-central nervous system (CNS) barriers in disease development, highlighting the importance of identifying genetic risk factors linked to cells forming the cerebrovasculature to advance this emerging area of research. The objective of this study is to identify PD genetic risk factors associated with blood-brain (BBB) and blood-cerebrospinal fluid (BCSFB) barriers, and to validate protein localization in human tissue and experimental models. To do so, we integrated genome-wide association studies and single nuclei RNA-sequencing datasets from the human postmortem substantia nigra (SN), midbrain, or cortical samples from control and PD donors. An in-depth bioinformatics analysis identified genes enriched in cell types that form the multicellular architecture of brain barriers, including CAVIN2, ANXA1, ANO2, and LRP1B. We further validated whether corresponding proteins were present in cell types associated with the blood-CNS barriers in human and mouse post-mortem tissues, as well as in iPSC-differentiated cells and choroid plexus organoids. Results showed that quantifying the proportion of endothelial cells expressing PD-related genes was under-evaluated at the transcript level compared to immunofluorescence analyses. In addition, we observed that CAVIN2 and ANXA1 proteins were more abundant at the vasculature of the substantia nigra vs. cortex, and CAVIN2 protein levels were reduced in PD vs. control human postmortem tissues. In contrast, the investigation of mouse postmortem samples demonstrated that the CAVIN2 protein is only present in a subset of mouse blood vessels, compared to nearly all vessels in human tissue. Similarly, mouse ANXA1 protein localizes to dopaminergic neurons of the substantia nigra and not at the vasculature, as seen in human tissue. The primary outcome of this study is the identification of PD-relevant risk genes specifically expressed at brain barriers and enriched in PD-relevant brain regions. The secondary outcome is the demonstration of poor transcript-protein correlation in - at least - a subset of PD risk factors, and a low interspecies conservation of protein localization for the selected candidates. In conclusion, the BBB and BCSFB may represent understudied contributors to PD, endothelial-specific proteins appear differentially regulated compared to transcripts, and experimental models require comprehensive validation to ensure relevance to the human condition.

neuroscience↗

Higher Angiotensin I Converting Enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major cause of death in the elderly. Cognitive decline due to Alzheimers disease (AD) is frequent in the geriatric population disproportionately affected by the COVID-19 pandemic. Interestingly, central nervous system (CNS) manifestations have been reported in SARS-CoV-2-infected patients. In this study, we investigated the levels of Angiotensin I Converting Enzyme 2 (ACE2), the main entry receptor of SARS-COV-2 in cells, in postmortem parietal cortex samples from two independent AD cohorts, totalling 142 persons. Higher concentrations of ACE2 protein and mRNA were found in individuals with a neuropathological diagnosis of AD compared to age-matched healthy control subjects. Brain levels of soluble ACE2 were inversely associated with cognitive scores (p = 0.02), markers of pericytes (PDGFR{beta}, p=0.02 and ANPEP, p = 0.007) and caveolin1 (p = 0.03), but positively correlated with soluble amyloid-{beta} peptides (A{beta}) concentrations (p = 0.01) and insoluble phospho- tau (S396/404, p = 0.002). No significant differences in ACE2 were observed in the 3xTgAD mouse model of tau and A{beta} neuropathology. Results from immunofluorescence and Western blots showed that ACE2 protein is mainly localized in neurons in the human brain but predominantly in microvessels in the mouse brain. The present data show that an AD diagnosis is associated with higher levels of soluble ACE2 in the human brain, which might contribute to a higher risk of CNS SARS-CoV-2 infection.

neuroscience↗

Deregulation of brain endothelial CD2AP in Alzheimer's disease impairs Reelin-mediated neurovascular coupling

Genetic variations in CD2-associated protein (CD2AP) predispose to Alzheimers disease (AD) but the underlying mechanisms remain unknown. Here, we show that a cerebrovascular loss of CD2AP is associated with cognitive decline in AD and that genetic downregulation of CD2AP in brain endothelial cells impairs memory function in two distinct mouse models. Mice with reduced CD2AP in brain microvessels display decreased resting cerebral blood flow, impaired functional hyperemia and vasomotion. In brain endothelial cells, CD2AP regulates the levels and signaling of ApoE receptor 2 elicited by Reelin glycoprotein. Activation of the CD2AP-ApoER2 pathway with Reelin mitigates the toxic effects of A{beta} on resting blood flow and vasomotion of brain vessels depleted of CD2AP. Thus, we demonstrate that deregulation of CD2AP perturbs specific functions and segments of the cerebral microvasculature and propose that targeting CD2AP molecular partners may offer refined therapeutic strategies for the treatment of AD.

neuroscience↗